Back

Efficacy and Safety of Pemvidutide in Patients with Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Dose-Specific Meta-Analysis of Randomized Controlled Trials

2025-12-23 gastroenterology Title + abstract only
View on medRxiv
Show abstract

BackgroundMetabolic dysfunction-associated steatohepatitis (MASH) is a prevalent and progressive liver disease with limited pharmacologic treatment options. Pemvidutide, a GLP-1-glucagon dual receptor agonist, has shown promise in targeting both hepatic steatosis and fibrosis. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of pemvidutide in adults with MASH. MethodsWe systematically searched PubMed, Scopus, Web of Science, and Cochrane CENTRAL through Decembe...

Predicted journal destinations